ProNAi Therapeutics, Inc. to Present Phase II Clinical Data at American Society of Hematology for PNT2258, a BCL2 Targeted Drug

ProNAi Therapeutics, Inc. a leader in nucleic acid therapeutics, announced that data from its ongoing Phase II clinical study of PNT2258, a novel BCL2 inhibitor, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), held in New Orleans December 7-10, 2013.

“We are very encouraged by the safety profile and the anti-tumor responses in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) treated with PNT2258,” stated Rich Messmann, ProNAi’s Chief Medical Officer.

Help employers find you! Check out all the jobs and post your resume.